BRAF and colorectal carcinoma: Investigating the predictive value of BRAF mutations in MSI-H/MMR-D CRC patients receiving nivolumab, Overman et al.,9 found that anti-PD-1-based therapy benefited patients similarly in subgroups with or without BRAF mutation.